BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 8199992)

  • 1. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.
    Cortes JE; Kantarjian H; O'Brien S; Robertson LE; Koller C; Hirsh-Ginsberg C; Stass S; Keating M; Estey E
    Cancer; 1994 Jun; 73(12):2946-52. PubMed ID: 8199992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of acute promyelocytic leukemia relapse in the ATRA era.
    Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
    Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
    Thomas X; Dombret H; Cordonnier C; Pigneux A; Gardin C; Guerci A; Vekhoff A; Sadoun A; Stamatoullas A; Fegueux N; Maloisel F; Cahn JY; Reman O; Gratecos N; Berthou C; Huguet F; Kotoucek P; Travade P; Buzyn A; de Revel T; Vilque JP; Naccache P; Chomienne C; Degos L; Fenaux P
    Leukemia; 2000 Jun; 14(6):1006-13. PubMed ID: 10865965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.
    Avvisati G; Lo Coco F; Diverio D; Falda M; Ferrara F; Lazzarino M; Russo D; Petti MC; Mandelli F
    Blood; 1996 Aug; 88(4):1390-8. PubMed ID: 8695858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-transretinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Kreze O
    Indian J Cancer; 2004; 41(3):125-8. PubMed ID: 15472411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone.
    Advani SH; Nair R; Bapna A; Gladstone B; Kadam P; Saikia TK; Parekh PM; Gopal R; Nair CN
    Am J Hematol; 1999 Feb; 60(2):87-93. PubMed ID: 9929098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
    Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
    Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene.
    Meloni G; Diverio D; Vignetti M; Avvisati G; Capria S; Petti MC; Mandelli F; Lo Coco F
    Blood; 1997 Aug; 90(3):1321-5. PubMed ID: 9242568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.
    Estey E; Thall PF; Pierce S; Kantarjian H; Keating M
    J Clin Oncol; 1997 Feb; 15(2):483-90. PubMed ID: 9053469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.
    Kanamaru A; Takemoto Y; Tanimoto M; Murakami H; Asou N; Kobayashi T; Kuriyama K; Ohmoto E; Sakamaki H; Tsubaki K
    Blood; 1995 Mar; 85(5):1202-6. PubMed ID: 7858250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age.
    Finsinger P; Breccia M; Minotti C; Carmosino I; Girmenia C; Chisini M; Volpicelli P; Vozella F; Romano A; Montagna C; Colafigli G; Cimino G; Avvisati G; Petti MC; Lo-Coco F; Foà R; Latagliata R
    Ann Hematol; 2015 Feb; 94(2):195-200. PubMed ID: 25186786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
    Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
    Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of molecular relapse in acute promyelocytic leukemia.
    Lo Coco F; Diverio D; Avvisati G; Petti MC; Meloni G; Pogliani EM; Biondi A; Rossi G; Carlo-Stella C; Selleri C; Martino B; Specchia G; Mandelli F
    Blood; 1999 Oct; 94(7):2225-9. PubMed ID: 10498592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG).
    Asou N; Adachi K; Tamura J; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Sakamaki H; Tsubaki K; Saito K; Ohno R
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S30-5. PubMed ID: 9272131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.
    Fenaux P; Chastang C; Chevret S; Sanz M; Dombret H; Archimbaud E; Fey M; Rayon C; Huguet F; Sotto JJ; Gardin C; Makhoul PC; Travade P; Solary E; Fegueux N; Bordessoule D; Miguel JS; Link H; Desablens B; Stamatoullas A; Deconinck E; Maloisel F; Castaigne S; Preudhomme C; Degos L
    Blood; 1999 Aug; 94(4):1192-200. PubMed ID: 10438706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
    Belhabri A; Thomas X; Wattel E; Chelghoum Y; Anglaret B; Vekhoff A; Reman O; Dombret H; Dhedin N; Michallet M; Fière D; Archimbaud E
    Hematol J; 2002; 3(1):49-55. PubMed ID: 11960396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).
    Asou N; Adachi K; Tamura U; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama U; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake H; Ohno R
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S65-71. PubMed ID: 11587370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of all-trans-retinoic acid alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukaemia.
    Colović MD; Janković GM; Elezović I; Vidović A; Bila JS; Novak A; Babić D
    Med Oncol; 1997 Jun; 14(2):65-72. PubMed ID: 9330265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.